SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff and repeated tests of its yearly lows are drawing attention amid concerns about heavy debt, costly financing, refinancing needs and insider selling, alongside broader doubts about AI-infrastructure spending. Traders are split: bears see financing risks as a threat to growth, while bulls point to its backlog and AI partnerships and view the selloff as overdone; analyst upgrades and ARKs buying have not dispelled skepticism.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding alongside semiconductor stocks after a steep, extended selloff, drawing dip buyers who see oversold conditions and continued AI-chip demand as support for a recovery. Others warn the bounce may be temporary, citing concerns about AI investment returns and debt, market uncertainty, and upcoming chip-sector earnings.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a semiconductor selloff, with traders focused on CEO Hock Tans warning that some AI investing resembles gambling and his comments about capital constraints. The remarks and worries about AI spending and financing have fueled bearish sentiment, while other traders see the pullback as a buying opportunity based on Broadcoms AI-chip growth; many also complain that the stock has lagged semiconductor peers.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention over concerns that its debt-funded AI data-center buildout and heavy capital spending could strain cash flow, amplified by widening credit-risk indicators and broader jitters around AI infrastructure financing. Traders are split between fears that spending and customer concentration pose serious risks and the view that Oracles cloud demand and backlog can eventually justify the investment, with some buying the selloff.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a prolonged post-IPO selloff, with traders citing lockup expirations and insider-share supply, a TD Cowen price-target cut, and concerns about OpenAI customer concentration, scaling, and Nvidia competition. Bears see continued selling pressure, while bulls argue the decline is overdone and point to Cerebras AI-chip technology and backlog.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile AI and semiconductor rebound, as traders debate whether credit strains at AI infrastructure firms such as CoreWeave and uncertain returns on data-center spending could undermine chip demand. Dip buyers see continued AI demand and upcoming hyperscaler earnings and GTC commentary as reasons for confidence, while skeptics warn that the rally may fade.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Discussion centers on Starknets quantum-resistance narrative and the possibility of moving from an Ethereum L2 to an independent L1, alongside claims of a quantum-resistant Bitcoin transaction test on mainnet. Bulls see the technology and Bitcoin/privacy applications as catalysts, while skeptics point to past dilution, token unlocks and sharp price swings.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas large equity offering has pressured shares, with traders citing dilution even as the capital is intended to support expansion. The selloff is being debated against the bullish AI and data-center demand outlook, prompting dip-buying while others remain concerned about volatility and the stocks valuation.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Scott Kirbys comments supporting a near-total inheritance tax have drawn sharp criticism, with some traders calling for a boycott of United. The discussion also focuses on the quarterly earnings report and recent share weakness, with traders divided between bearish concerns and potential upside if results and guidance reassure investors.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound in the Nasdaq-100 after a sharp AI-related selloff is driving attention, with traders pointing to strength in semiconductors and megacaps ahead of major technology earnings. The community is divided over whether the bounce signals a recovery or is a bull trap, amid continuing concerns about AI spending and market weakness beneath the headline indexes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical stage drug programs, today announced that Lantern management will be presenting...

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC trial of LP-300. The Taiwan Food and Drug Administration (TFDA) approved...

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern, the Company or we), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced the closing of its previously announced registered direct offering of 3,669,725...

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, will present the growth plan for Open-Medicine AI (OMAI) in a live webinar today at 12:30 PM Eastern. Open Medicine AI is the...

Lantern Pharma Secures USPTO Notice of Allowance for LP284 Treatment Patent in Aggressive BCell Lymphomas

Lantern Pharma Inc. (NASDAQ: LTRN), an AIdriven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application...

Lantern Pharma to Present Open-Medicine AI a Multi-Agentic Platform for End-to-End Therapeutic Development Business Model, Roadmap, and Value Proposition on September 23

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business...

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational...

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR and Open-Medicine AI platforms with multiple clinical stage drug programs, today announced that it will host its second quarter 2026...

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lantern Pharma Board...

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Lantern Pharma Inc

Top Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Soaring Before The Bell

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for EL-22 and EL-32, targeting muscle and lean mass preservation.</li><li>Iterum Therapeutics announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.</li><li>Lantern Pharma said the FDA cleared its Investigational New Drug application for STAR-001, a targeted therapy for relapsed or refractory CNS cancers.</li></ul>U.S. equities were in the green in Monday’s pre-market trade amid the ongoing tensions in the Middle East, with President Donald Trump stating on Sunday that Iran had agreed to the 15-point ceasefire plan “for the most part.”At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.49%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.42%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.47%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ELAB">PMGC Holdings Inc. (ELAB)</a>PMGC Holdings shares soared more than 66% in Monday’s pre-market session. The company announced on Friday that its wholly-owned subsidiary, NorthStrive Biosciences, has amended its existing agreement with MOA Life Plus for human clinical trials of its lead candidate EL-22, as well as EL-32, to study the preservation of muscle and lean mass.<a href="https://stocktwits.com/symbol/ELAB">ELAB stock</a> is down 95% year-to-date.<a href="https://stocktwits.com/symbol/ITRM">Iterum Therapeutics PLC (ITRM)</a>Iterum Therapeutics shares more than doubled to soar 110% in Monday’s pre-market trade. The company announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.<a href="https://stocktwits.com/symbol/ITRM">ITRM stock</a> is down 90% year-to-date.<a href="https://stocktwits.com/symbol/LTRN">Lantern Pharma Inc. (LTRN)</a>Lantern Pharma shares gained more than 17% in Monday’s pre-market session. The company announced on Friday that its CEO Panna Sharma continues to serve the Dallas-based biopharmaceutical company. It also announced that the U.S. Food and Drug administration (FDA) cleared its Investigational New Drug (IND) application for STAR-001, its treatment for patients with relapsed or refractory central nervous system (CNS) malignancies.<a href="https://stocktwits.com/symbol/LTRN">LTRN stock</a> is down 63% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bur-stock-sinks-after-us-appeals-court-ruling-argentina-ypf-connection/cZ3HJ4aRIm7">BUR Stock Sinks 40% Following A Reported US Appeals Court Ruling — What Is The Argentina Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. equities gained in Monday’s pre-market trade after President Donald Trump stated that Iran had agreed to the 15-point proposal for the most part.

PMGC Holdings Inc.

Iterum Therapeutics Plc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$0.6413
Prev Close	$0.6684
Open	$0.6521
Dividend Yield	0.00%
50-Day Moving Average	$1.64
Beta	1.92
Avg. Volume	275,639.08
PE Ratio	-0.40

52-Week High	$4.34
52-Week Low	$0.625
Market Capitalization	$9.98M
EPS (Annual)	-$1.57
Price to Book	-2.54
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

LTRN Fundamentals